Logo image of IRD

OPUS GENETICS INC (IRD) Stock Fundamental Analysis

USA - NASDAQ:IRD - US67577R1023 - Common Stock

1.96 USD
-0.03 (-1.51%)
Last: 10/10/2025, 9:36:11 PM
1.96 USD
0 (0%)
After Hours: 10/10/2025, 9:36:11 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IRD. IRD was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of IRD have multiple concerns. IRD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IRD had negative earnings in the past year.
In the past year IRD has reported a negative cash flow from operations.
IRD had negative earnings in 4 of the past 5 years.
In the past 5 years IRD reported 4 times negative operating cash flow.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

With a Return On Assets value of -150.72%, IRD is not doing good in the industry: 85.66% of the companies in the same industry are doing better.
IRD has a worse Return On Equity (-333.51%) than 73.00% of its industry peers.
Industry RankSector Rank
ROA -150.72%
ROE -333.51%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IRD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

2

2. Health

2.1 Basic Checks

IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IRD has been increased compared to 5 years ago.
There is no outstanding debt for IRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

IRD has an Altman-Z score of -4.08. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.08, IRD is in line with its industry, outperforming 42.46% of the companies in the same industry.
IRD has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
IRD has a Debt to Equity ratio of 0.06. This is in the lower half of the industry: IRD underperforms 61.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -4.08
ROIC/WACCN/A
WACC9.38%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

IRD has a Current Ratio of 1.90. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
IRD has a Current ratio of 1.90. This is in the lower half of the industry: IRD underperforms 76.91% of its industry peers.
A Quick Ratio of 1.90 indicates that IRD should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.90, IRD is doing worse than 74.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for IRD have decreased strongly by -58.18% in the last year.
The Revenue has decreased by -6.28% in the past year.
IRD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 165.10% yearly.
EPS 1Y (TTM)-58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-6.28%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%159.17%

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
IRD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.09% yearly.
EPS Next Y47.66%
EPS Next 2Y27.69%
EPS Next 3Y15.5%
EPS Next 5Y14.87%
Revenue Next Year61.29%
Revenue Next 2Y74.86%
Revenue Next 3Y30.19%
Revenue Next 5Y34.09%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as IRD's earnings are expected to grow with 15.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.69%
EPS Next 3Y15.5%

More info and screens

0

5. Dividend

5.1 Amount

IRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPUS GENETICS INC

NASDAQ:IRD (10/10/2025, 9:36:11 PM)

After market: 1.96 0 (0%)

1.96

-0.03 (-1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10
Inst Owners20.88%
Inst Owner ChangeN/A
Ins Owners7.02%
Ins Owner Change56.89%
Market Cap123.58M
Analysts80
Price Target8.16 (316.33%)
Short Float %0.2%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.5%
Min EPS beat(2)4.95%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)10.31%
Min EPS beat(4)-20.9%
Max EPS beat(4)42.04%
EPS beat(8)4
Avg EPS beat(8)-21.76%
EPS beat(12)6
Avg EPS beat(12)-14.42%
EPS beat(16)9
Avg EPS beat(16)-8.54%
Revenue beat(2)1
Avg Revenue beat(2)5.08%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)39.62%
Revenue beat(4)3
Avg Revenue beat(4)29.95%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)67.33%
Revenue beat(8)4
Avg Revenue beat(8)28.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.84%
EPS NY rev (1m)12.75%
EPS NY rev (3m)32.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.01
P/FCF N/A
P/OCF N/A
P/B 7.07
P/tB 7.07
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.24
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -150.72%
ROE -333.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -4.08
F-Score2
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y47.66%
EPS Next 2Y27.69%
EPS Next 3Y15.5%
EPS Next 5Y14.87%
Revenue 1Y (TTM)-6.28%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%159.17%
Revenue Next Year61.29%
Revenue Next 2Y74.86%
Revenue Next 3Y30.19%
Revenue Next 5Y34.09%
EBIT growth 1Y-152.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-247.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-247.16%
OCF growth 3YN/A
OCF growth 5YN/A